Our results indicate that HDAC inhibitors may not be a viable therapeutic treatment option in NSCLC, at least as a single entity given that in our experience, both SAHA and TSA increase the expression of both IL-23 and IL-23R levels. Here, IL23R is linked to non-small cell lung carcinoma.